August 2021

Cost-effectiveness of Intensification With SGLT2 Inhibitors for Type 2 Diabetes

August 25, 2021

WEB EXCLUSIVE

Adding a sodium-glucose co-transporter 2 (SGLT2) inhibitor dominated switching to a glucagon-like peptide 1 receptor agonist over the lifetimes of patients with type 2 diabetes not at glycated hemoglobin A1c target after treatment with metformin plus a dipeptidyl peptidase-4 inhibitor.

Cost-effectiveness of Nivolumab in Patients With NSCLC in the United States

August 24, 2021

WEB EXCLUSIVE

This article presents a cost-effectiveness analysis of nivolumab vs docetaxel from the US payer perspective in non–small cell lung cancer (NSCLC) based on randomized phase 3 studies with a minimum 5 years of follow-up.

Modeling Financial Outcomes and Quantifying Risk in Episode-Based Payment Models

August 23, 2021

WEB EXCLUSIVE

This article provides a description of prospective financial simulation methodology and use cases with empirical data for episode-based bundled payments, including implications for contract negotiations and value-based care redesign.

Mortality Risk Stratification Helps Identify Patients With COVID-19 at Risk of Adverse Outcomes

August 13, 2021

LETTERS TO THE EDITORS

Mortality risk stratification can identify patients with COVID-19 who are at higher risk of mortality, discharge to skilled nursing facility, and readmission, and may benefit from focused intervention strategies.